CheckMate 274: Estimating the Underlying Cure Fraction for Patients With High-Risk MIUC

Daniel M. Geynisman, MD, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Center, highlights his recent research into long-term survival with adjuvant nivolumab for patients with high-risk MIUC. The CheckMate 274 study utilized mixture cure models to estimate the underlying cure fraction following radical resection.